BridgeMD
New treatment option for Chronic Kidney Disease Requiring Hemodialysis
Official title Benefits of a Renal Rehabilitation Program Adapted to Uremic Patients on Daily Hemodialysis at Low Dialysate Flow Rate.
ClinicalTrials.gov ID: NCT07413315
What this study is testing
- What it's testing
- The concept of renal rehabilitation has become increasingly important with the increasing age of patients with severe or even terminal chronic kidney disease (CKD). It combines physical exercise and nutritional monitoring programs for patients with terminal CKD who are most often treated with conventional hemodialysis (HD) at a rate of 3 sessions of 4 hours per week.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- patient with terminal chronic kidney disease requiring hemodialysis treatment
- patient recently hospitalized for an acute medical event.
You likely can't join if
- dementia/mild cognitive impairment (MMSE \< 20/30)
- decompensated psychiatric pathology and/or behavioral disorders
- pregnant woman
- recovery of renal function allowing interruption of helodialysis sessions
- candidate for neurological rehabilitation
- patient with recent spinal cord injury
See the full eligibility criteria
- patient with terminal chronic kidney disease requiring hemodialysis treatment
- patient recently hospitalized for an acute medical event.
- dementia/mild cognitive impairment (MMSE \< 20/30)
- decompensated psychiatric pathology and/or behavioral disorders
- pregnant woman
- recovery of renal function allowing interruption of helodialysis sessions
- candidate for neurological rehabilitation
- patient with recent spinal cord injury
- patient with absolute and/or relative contraindication to performing a stress test
- severe or poorly tolerated cardiac rhythm disorder
- severe or symptomatic obstruction to left ventricular ejection
- decompensated heart failure
- acute myocarditis, pericarditis or endocarditis
- acute aortic dissection
- high-risk emboligenic intracardiac thrombus
- significant stenosis of the common trunk
- ventricular aneurysm
- supraventricular tachycardia with poorly controlled ventricular rate, acquired high-degree or complete block
- obstructive cardiomyopathy with high resting gradient
- recent stroke or TIA
- acute venous thrombosis with or without pulmonary embolism
- poorly controlled clinical condition, such as marked anemia, significant electrolyte disturbance, hyperthyroidism, etc.
- lack of cooperation from the patient
- Blood pressure \> 200/110 mmHg
The study team makes the final eligibility decision.
Where it's taking place
- Brussels, Belgium
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brussels, Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.